Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Repaglinide Krka

Repaglinide Krka 0.5 mg tablets Repaglinide Krka 1 mg tablets Repaglinide Krka 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-210699 · Präparat HOS-154571

In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. Consequently metabolism, and by that clearance of repaglinide, may be altered by substances which influence these cytochrome P-450 enzymes via inhibition or induction. Special care should be taken when inhibitors of both CYP2C8 and 3A4 are co- administered simultaneously with repaglinide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.